Vcare 2024 Annual Review
Published Time:
2025-01-27 18:01
Source:
I. Innovative Drug R&D Has Witnessed Multiple Significant Advances
① Vicagrel Capsules (anti-platelet):
China: Preparing NDA submission
US: IND approved by FDA
② VC005 Tablets (next-gen selective JAK1 inhibitor):
Phase III for moderate-severe atopic dermatitis: 1st patient enrolled
Phase III for ankylosing spondylitis: Initiated
③ VC005 Gel (topical JAK1 inhibitor):
Phase II for mild-moderate atopic dermatitis: Initiated
II. Patent Layout for Innovative Drugs
Filed 10 patent applications; Granted 7 patents.
III. Sustained Revenue Growth
2024 revenue: ~RMB 440 million; Contract value: ~RMB 690 million.
IV. Strategic Corporate Development
① Closed Series C+ financing (~RMB 200M); Completed shareholding reform.
② Commenced photovoltaic power project construction.
③ Completed warehouse expansion & lab renovation.
④ Tianshu Pharmaceutical Phase I facility passed final acceptance.
V. Accelerated Group Digitalization
① Completed Phase II: CRM platform & data middleware established.
② Launching Phase III: R&D & production project management systems.
VI. Employee Care Highlights
① Organized 8 cultural events
② Held 12 Happy Hour activities
③ Completed 115 promotions
④ ~70 employees received equity incentives
⑤ Conducted 400+ internal trainings
⑥ Hosted 10+ external expert lectures
VII. Honors & Qualifications
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
Nanjing Vcare Honored As: Top 20 CRO Enterprises in China; Jiangsu Provincial Three-Star Cloud-Adopted Enterprise; Nanjing Engineering Research Center for Synthetic Biology & Flow Chemistry
Related News
17
2024
/
10
Jiangsu Vcare's New-generation TRK Inhibitor VC004 Obtains IND Approval from the US FDA
On October 16, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (referred to as "Jiangsu Vcare")'s independently developed new-generation anti-resistant TRK inhibitor VC004 achieved a significant milestone progress, and the project officially obtained the Investigational New Drug (IND) permission from the US Food and Drug Administration (FDA). This fully demonstrates Jiangsu Vcare's excellent drug research and development capabilities and is a successful practice of the company's strategies based on original innovation, high-quality standards, and a global layout.
View Details
24
2024
/
09
Jiangsu Vcare’s Next-Generation TRK Inhibitor VC004 IND Application was accepted by the US FDA
At the end of September 2024, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that the US FDA has officially accepted the Investigational New Drug (IND) application of its independently developed new-generation anti-resistant TRK inhibitor VC004. This milestone paves the way for the global commercialization strategy.
View Details
09
2024
/
09
Recently, the Ministry of Industry and Information Technology (MIIT) announced the sixth batch of National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises, andJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was successfully selected. Thisnational-levelhonor fully demonstrates that under its "dual-core business model," Jiangsu Vcare's scientific research capabilities, independent innovation capacity, market leadership, and future development potential have received official high recognition.
View Details
16
2024
/
08
Jiangsu Vcare Announces Successfully Unblinding of VC005 Topical Gel Clinical Phase I Data
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful unblinding of Phase I clinical data for its self-developed VC005 gel, a second-generation selective JAK1 inhibitor, in the topical treatment of mild-to-moderate atopic dermatitis (AD). The results demonstrated exceptional safety and significant efficacy.
View Details
14
2024
/
08
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced positive topline data from its Phase II clinical trial of VC005 tablets, a second-generation selective JAK1 inhibitor, for the oral treatment of moderate-to-severe atopic dermatitis (AD).
View Details
19
2024
/
07
Announcement on Company Name Change by Jiangsu Vcare Pharmatech Co., Ltd.
July 12, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (hereinafter referred to as "the Company") has completed the industrial and commercial registration for its name change and obtained the renewed Business License issued by the Administrative Approval Bureau of Nanjing Jiangbei New Area.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn